Joe

[Ghana Armed Forces @GhArmedForces]

As of 25 June 2026, 89.5 km (50.9%) of the Accra Kumasi Expressway Corridor has been cleared. This milestone was reached in 9 weeks, using just 45% of the estimated project duration. The remaining 86.1 km corridor will be completed over the next 13 weeks.

[Tech In Twi @tech_twi]

Pass a law that makes these actions criminal offenses, punishable by fines of over GH¢10,000 or months in jail. These kinds of people do not deserve to get away with such actions. People die every year because of flooding. This should be treated as a criminal offense.

[Joe @medindi_JB]

@thenanaaba The water just marrying everything in the guys compound. 🤣
House is gone, room is next.

[Joe @medindi_JB]

@askghmedia Why didn’t you add the part where he said they shouldn’t forget his catalyst?
Was that catalyst fulfilled?
If not let’s see what happens next. We hope for the best.

[Joe @medindi_JB]

@Freshum @Listo_Mens @bra_dhope Speak to him?
Kick him off the team.

[Joe @medindi_JB]

@obiMpenaAustine Covid vaccinated?

[Joe @medindi_JB]

@obiMpenaAustine First question I always ask for such deaths is that was she vaccinated?

[Joe @medindi_JB]

@callmeoheneba @kwakuasanteb Yeah it took me a long time before I was able to determine it was because of that. However why don’t they work on that to get it resolved?
And I think they need to get iPhone users informed.

[Joe @medindi_JB]

@Crazymoments01 So the leech was having a meal in his voice box? 😱

[Joe @medindi_JB]

@yourMPgabbi @obiMpenaAustine @angelgooner @NYboateng @af_ia_blue Can you get only the panel without the batteries?
Just for usage during the day?
Is that even feasible???

[Joe @medindi_JB]

@tech_twi USA 2 Paraguay 1

[Joe @medindi_JB]

@gyaigyimii They want to go bek home quickly.

[Joe @medindi_JB]

I think we need to takeoff the Africa from South Africa and rename it to“Pacific North”
We’re taking them out of Africa 🤣

@gyaigyimii @wode_maya

[Joe @medindi_JB]

@grok @wR_RamazanKoylu @ntahabercom I know @grok will not respond to me however if fluoride in toothpaste isn’t healthy for the skin how’s it healthy for the mouth?

[Joe @medindi_JB]

@kwasieshun142 So who should he use since there’s no male student there?

[KOJO DYNAMIC 𓃵 @AnnanPerry]

Listen to Dr Cassiel Ato Forson as he sat with Bloomberg to discuss Ghana’s economic reforms and hints of a new policy named “the new economy”.

[Joe @medindi_JB]

@withAlvin__ You don’t even require an AI to do this work. I wonder why they are wasting their energy for this one.
Just some little mechanical engineering can get a machine doing this work.

[Sam Okudzeto Ablakwa @S_OkudzetoAblak]

We urge Ghanaian CEOs and Entrepreneurs to support our JOBS INITIATIVE for our brothers and sisters being evacuated from South Africa.

Already, 120 job offers have been secured.

Kindly call our Delivery Unit.

Ghana always cares.

For God and Country.

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.

@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

[Joe @medindi_JB]

@InterestingSTEM Is if possible for fibroids?